ArticleProceedings of the National Academy of Sciences of the United States of America2000
In vivo natural killer cell activities revealed by natural killer cell-deficient mice.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 417 citations in OpenAlex.
- CD127International journal of molecular sciences · 2026Article
- iPSCs derived sEVs ameliorate NK cell senescence by targeting CISH-STAT3.Stem cell research & therapy · 2025Article
- Apoptotic cells promote circulating tumor cell survival and metastasis.Communications biology · 2025Article
- Exercise boost after surgery improves survival in model of metastatic breast cancer.Frontiers in immunology · 2025Article
- Decoding immune cell interactions during cardiac allograft vasculopathy: insights derived from bioinformatic strategies.Frontiers in cardiovascular medicine · 2025Review
- Generation and characterization of a tamoxifen-inducible lineage tracing toolFrontiers in immunology · 2025Article
- Natural Killer cells at the frontline in the fight against cancer.Cell death & disease · 2024Review
- Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity.Nature communications · 2024Article
- Cancer Immunotherapy with Lipid Nanoparticles Loaded with a Stimulator of Interferon Genes Agonist against Renal Tumor Lung Metastasis.Pharmaceutics · 2023Article
- Natural killer cells in the lung: potential role in asthma and virus-induced exacerbation?European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Synergistic Effect of Ginsenoside Rh2 Combines with Ionizing Radiation on CT26/Pharmaceuticals (Basel, Switzerland) · 2023Article
- Locally sourced: site-specific immune barriers to metastasis.Nature reviews. Immunology · 2023Review
- Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer.Pharmaceutics · 2023Review
- Roles of Virtual Memory T Cells in Diseases.Immune network · 2023Review
- Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.Frontiers in immunology · 2023Article
- Harnessing NK Cells to Control Metastasis.Vaccines · 2022Review
- Circadian Disruption and Consequences on Innate Immunity and Inflammatory Response.International journal of molecular sciences · 2022Review
- Physical Activity as the Best Supportive Care in Cancer: The Clinician's and the Researcher's Perspectives.Cancers · 2022Review
- A general toxicity and biodistribution study of human natural killer cells by single or repeated intravenous dose in severe combined immune deficient mice.Toxicological research · 2022Article
- A New Functional Screening Platform Identifies Colistin Sulfate as an Enhancer of Natural Killer Cell Cytotoxicity.Cancers · 2022Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies of natural killer (NK) cell function in vivo have been challenging primarily due to the lack of animal models in which NK cells are genetically and selectively deficient. Here, we describe a transgenic mouse with defective natural killing and selective deficiency in NK1.1(+) CD3(-) cells. Despite functionally normal B, T, and NK/T cells, transgenic mice displayed impaired acute in vivo rejection of tumor cells. Adoptive transfer experiments confirmed that NK1.1(+) CD3(-) cells were responsible for acute tumor rejection, establishing the relationship of NK1.1(+) CD3(-) cells to NK cells. Additional studies provided evidence that (i) NK cells play an important role in suppressing tumor metastasis and outgrowth; (ii) NK cells are major producers of IFNgamma in response to bacterial endotoxin but not to interleukin-12, and; (iii) NK cells are not essential for humoral responses to T cell-independent type 2 antigen or the generalized Shwartzman reaction, both of which were previously proposed to involve NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.